Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 12, 2022

View Archived Issues

CD22 aberrant splicing confers resistance to therapy in B-ALL

Dysregulation of the tRNA synthetase modulator NOTCH1 behind T-ALL pathogenesis

Discovery of novel hybrid compounds as antitubercular agents

TuA-derived hPep elicits long-term anticancer immunity in mice

Leo Pharma discloses IL-17 modulators

Amgen and Arrakis collaborate to discover and develop targeted RNA degrader therapeutics

Anaxis Pharma patents MLKL inhibitors

Abbisko Therapeutics identifies new PD-1/PD-L1 interaction inhibitors

Betta Pharmaceuticals synthesizes new HIF-2alpha inhibitors

Wigen Biomedicine Technology presents new CDK inhibitors

CD6-ALCAM pathway is a therapeutic target in SLE

Methamphetamine harnessed for good in BBB transport

REVTx-99 demonstrates in vitro antiviral activity against SARS-CoV-2

PostEra and Pfizer expand strategic collaboration

VCAM-1-targeting polyelectrolyte complex enhances therapeutic efficacy of miR-92a inhibitors in vivo

Dren Bio and Pfizer collaborate to discover and develop bispecific antibodies for cancer

ABL and Sanofi enter collaboration and license agreement for ABL-301

G3PP is a therapeutic target for age-related metabolic diseases

Neogene licenses portfolio of TCRs targeting KRAS and TP53 mutations from NCI

A simple method for the synthesis of isoxazole derivatives with in vitro antitumor activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...